Mexico City. The Dengvaxia® vaccine (Tetravalent live attenuated virus vaccine against dengue) is being applied to children under 9 years of age, alerted the Federal Commission for the Protection against Sanitary Risks (Cofepris), a body that issued a “notice” tonight risky”.
He explained that it was detected that the biological is being applied by general practitioners and specialists, including pediatricians, to infants under 9 years of age, “which represents a risk to the health of this population group.”
Cofepris detailed in a message addressed to both medical personnel and the general population that in accordance with the authorization issued through the sanitary registry 401M2015 SSA IV granted to Sanofi Aventis de México, SA de CV, said vaccine is indicated for people in the age range from 9 to 45 years living in dengue endemic areas.
Since the Dengvaxia® vaccine is not always used correctly, Cofepris issued various recommendations:
Among them is that the biological “must be applied under medical evaluation and supervision, in accordance with the indications established in the health registry, in addition to the fact that the treating physician must adhere to current scientific evidence to determine its administration.”
After reiterating that Dengvaxia® “should not be applied to children under 9 years of age, he urged to consult the instructive annex contained in the packaging” of the Dengvaxia® vaccine prior to its application.
He also called to verify that the vaccine packaging is in Spanish, has a health registry, and that the batch number and expiration date match between the secondary packaging and the vial with lyophilized powder.
He also said that the Dengvaxia® data sheet available online should be reviewed.
He maintained that “never” should “purchase medicines on social networks, sales platforms and other Internet sites, especially those in which an assessment, prescription and medical supervision are necessary, and that are also offered at a lower price than in the market.
The federal commission will maintain health surveillance actions and will inform the population in the event of identifying new evidence, in order to prevent products, companies or establishments from failing to comply with current health legislation and representing a risk to the health of the population.
The technical data sheet of the vaccine states that Dengvaxia® is indicated to prevent the disease caused by serotypes 1,2,3 and 4 of the dengue virus, and that the primary vaccination schedule consists of three injections of a reconstituted dose (0.5 milliliters ) administered at six-month intervals.
2023-09-02 04:32:00
#Cofepris #issues #risk #warning #childhood #vaccination #biological #Dengvaxia
